Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA ) 1.080 -0.050 (-4.42%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about ZyVersa Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 8 Next > Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 18, 2024 Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 18, 2024 Via Benzinga Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today? January 17, 2024 ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis. Via Benzinga Why ZyVersa Therapeutics Shares Are Down 40% December 07, 2023 ZyVersa Therapeutics Inc (NASDAQ: ZVSA) shares are trading lower by 43.7% to $1.20 Thursday morning. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 17, 2024 Via Benzinga ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis January 17, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access January 10, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets January 04, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 January 03, 2024 From ZyVersa Therapeutics Via GlobeNewswire This Biotech Is Targeting Indications Worth $70 Billion December 22, 2023 Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access. Via Benzinga Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 19, 2023 Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... Via Benzinga Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket December 19, 2023 Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in... Via Benzinga ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024” December 18, 2023 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 December 14, 2023 From ZyVersa Therapeutics Via GlobeNewswire Dow Surges 100 Points; Ciena Posts Upbeat Earnings December 07, 2023 U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Thursday. The Dow traded up 0.28% to 36,155 while the NASDAQ rose 1.41% to 14,346.47. The S&P... Via Benzinga Topics Stocks Exposures US Equities Gold Moves Lower; Dollar General Earnings Beat Estimates December 07, 2023 U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 36,077.32 while the NASDAQ rose 1.09% to 14,301.04.... Via Benzinga Topics Earnings Stocks Exposures Financial US Equities ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes December 07, 2023 From ZyVersa Therapeutics Via GlobeNewswire Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session December 07, 2023 Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. Via Benzinga Nasdaq Jumps Over 100 Points; US Jobless Claims Edge Higher December 07, 2023 U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 36,068.53 while the... Via Benzinga Topics Stocks Exposures US Equities Rivian (RIVN) Stock Just Scored a New ‘Buy’ Rating December 07, 2023 Rivian stock is gaining on Thursday after Stifel weighed in on RIVN shares with a buy rating and set a price target of $25 per share. Via InvestorPlace Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today? December 07, 2023 ZyVersa Therapeutics stock is falling hard on Thursday after the company priced a public offering for shares of ZVSA this morning. Via InvestorPlace Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket December 07, 2023 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday December 07, 2023 It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! Via InvestorPlace ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering December 06, 2023 From ZyVersa Therapeutics Via GlobeNewswire Shopify (SHOP) Stock Falls Following Analyst Downgrade December 06, 2023 Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt. Via InvestorPlace Why Is Pharvaris (PHVS) Stock Up 36% Today? December 06, 2023 Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants. Via InvestorPlace Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today? December 06, 2023 ZyVersa Therapeutics stock is rising with heavy trading of ZVSA shares after a paper was published in a peer-reviewed journal. Via InvestorPlace ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways December 06, 2023 From ZyVersa Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session November 30, 2023 Via Benzinga ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock November 30, 2023 From ZyVersa Therapeutics Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
